# XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

> **NCT06792435** · PHASE1,PHASE2 · RECRUITING · sponsor: **Evopoint Biosciences Inc.** · enrollment: 240 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma Metastatic
- Lung Cancer (NSCLC)
- Ovarian Cancer
- Colorectal Cancer Metastatic
- Biliary Tract Cancer
- Gastric Carcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** XNW27011
- **DRUG:** XNW27011

## Key facts

- **NCT ID:** NCT06792435
- **Lead sponsor:** Evopoint Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-27
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06792435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06792435, "XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06792435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*